

Fellow Publications

IU HEMATOLOGY ONCOLOGY FELLOWSHIP



Hematology/Oncology Fellow ASCO abstracts: 2005-2012

Shahda S, Barrett MT, Lenkiewicz E, Evers L, Posner R, Aziz M, Weiss GJ, Jameson G, Von Hoff DD, Ramanathan RK: Analysis of the Pancreatic cancer (PC) Genome by Immunohistochemistry (IHC) and Comparative Genome Hybridization (CGH) in Patients with Long Term Survival with Metastatic Disease (mPC) Treated on a Phase II Molecular Profiling Trial. (AACR 2013 annual meeting abstract #1911).

Myre B, Yu M, Picus J, Bufill JA, Harb WA, Burns M, Spittler AJ, Zeng Y, Currie CR, Chiorean EG. Phase I study of everolimus (RAD001) with irinotecan (Iri) and cetuximab (C) in second-line metastatic colorectal cancer: Hoosier Oncology Group GI05-102. J Clin Oncol 29: 2011 (suppl 4; abstract 523).

Riggs HD, Lane KA, Loehrer PJ, Hui S, Rawl S, Ormerod A, Weiner M: Delivery of Adjuvant Chemotherapy (AC) to Veterans with Resected Colon Cancer. (submitted to 2012 ASCO)

Riggs H, Rawl S, Loehrer P, Lane K, Hui S, Weiner M: Early Discontinuation of Adjuvant Chemotherapy among Veterans with Colon Cancer. (submitted to the 2012 American Geriatric Society Meeting)

Schmitt J, Sommers S, Fisher W, Ansari R, Robin E, Koneru K, McClean J, Liu Z, Hanna N. Sunitinib plus paclitaxel in patients with advanced esophageal cancer: a phase II study from the Hoosier Oncology Group. Proc Am Soc Clin Oncol 2011;29 (abstract e14661).

Shahda S, Yu M, Picus J, Bufill JA, Harb WA, Burns M, Spittler AJ, Flynn J, Zeng Y, Vance GH, Wu J, Currie CR, Loehrer PJ, Chiorean EG: Phase I study of Everolimus (RAD001) with Irinotecan (Iri) and Cetuximab (C) in 2nd Line Metastatic Colorectal Cancer (mCRC): Hoosier Oncology Group GI05-102, Final Report (Abstract #3587, Proc Am Soc Clin Oncol, 6/2011)

B.P. Mulherin, M.J. Brames, L.H. Einhorn. Long-term survival with paclitaxel and gemcitabine for germ cell tumors after progression following high-dose chemotherapy with tandem transplants. ASCO 2011 (abstract #4562)

Asirwa FC and Einhorn LH: Salvage therapy with high dose chemotherapy and peripheral blood stem cell transplant in patients with primary mediastinal non-seminomatous germ cell tumors. ASCO 2011 (abstract #e15119)

Jain A, Brames MJ, Vaughn D, and Einhorn LH: Phase II clinical trial of oxaliplatin and bevacizumab in refractory germ cell tumors. ASCO 2011 (abstract #4579)

Pant-Purohit M, Brames MJ, Abonour R and Einhorn L: Tumor marker rise during second course high dose chemotherapy in recurrent testicular cancer: Outcome analysis. ASCO 2011 (abstract #4612)

Ramasubbiah R, Brames MJ, Johnson E, Einhorn LH, et al.: Phase II study of oxaliplatin + bevacizumab in refractory germ cell tumors. ASCO 2010. Ramasubbiah R, Picus J, Bufill J, Loehrer PJ, Johnston EL, Flynn J, Currie CR, Tong Y, Yu M, Chiorean EG: Interim Analysis of a Phase II Trial of Erlotinib (E) in Combination with Docetaxel (D) in Advanced Hepatocellular (HCC) and Biliary Tract Carcinomas (BTC): Hoosier Oncology Group GI06-101. Poster Presentation - 2010 Gastrointestinal Cancers Symposium, 1/2010, Orlando FL, (Abstract #251)

Jayaram N, Neubauer M, Johnson C, Breen T, Williams C, Hanna N. The impact of PET imaging on outcomes in patients with stage III non-small cell lung cancer (NSCLC) treated with chemoradiation: a subset analysis of HOG LUN 01-24/USO-023. Proc Am Soc Clin Oncol 2010;28 (abstract 7065).

Schubert CC, Riggs H, Callahan CM, Loehrer PJ, Westmoreland GR: Building the Geriatrics in Oncology Program at Indiana University. American Geriatrics Society Annual Meeting, Orlando FL, 5/2010 (Poster Session #C116, Abstract #753966)

Baghdadi T, Hanna N, Bhatia S, McClean J, Johnson C, Yu M, Taber D, Harb W. Erlotinib and bevacizumab in chemotherapy-naïve performance status 2 patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 2009;27 (Abstract e19082).

Casey E, Harb W, Bradford D, Bufill J, Nattam S, Patel J, Fisher W, Latz J, Wu J, Hanna N. Randomized, double blind, multicenter, phase II study of pemetrexed (PEM), carboplatin (CARBO), bevacizumab (BEV) with enzastaurin (ENZ) or placebo (PBO) in chemotherapy-naïve patients with stage IIIB/IV non-small cell lung cancer (NSCLC): Hoosier Oncology Group (HOG) LUN06-116. Proc Am Soc Clin Oncol 2009;27 (Abstract 8035).

Agarwala A, Hanna N, McCollum A, Bechar N, DiMaio M, Yu M, Tong Y, Becerra C, Choy H. Preoperative cetuximab and radiation (XRT) for patients (pts) with surgically resectable esophageal and gastroesophageal junction (GEJ) carcinomas: A pilot study from the Hoosier Oncology Group and the University of Texas Southwestern. Proc Am Soc Clin Oncol 2009;27 (Abstract 4557).

Radaideh S, Cook V, Kesler KA and Einhorn LH: Outcome following resection for patients with primary mediastinal nonseminomatous germ cell tumors and rising serum tumor markers postchemotherapy. Proc Amer Soc Clin Oncol 26:259, 2008 (abstract #5038)

Salter JT, Lewis D, Sgroi M, Hanna N, McCollum A, Nechar N, DiMaio M, Hammoud Z, Yu M, Choy H, Becerra C. Preoperative cetuximab and radiation (XRT) for patients with surgically resectable esophageal and gastroesophageal junction carcinomas: a pilot study from the Hoosier Oncology Group and the University of Texas-Southwestern. Proc Am Soc Clin Oncol 2008;26:229s (Abstract 4564).

Mina L, Neubauer M, Ansari R, Govindan R, Einhorn L, Fisher W, Bruetman D, Chowhan N, Johnson C, Hanna N. Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01-24/USO-023-updated results. Proc Am Soc Clin Oncol 2008;26:401s (Abstract 7519).

Jalal S, Bhatia S, Einhorn L, Ansari R, Bechar N, Govindan R, Koneru K, Bedano P, Wu J, Hanna N. Paclitaxel plus Bevacizumab in patients with chemosensitive relapsed small cell lung cancer (SCLC): A safety, feasibility and efficacy trial from the Hoosier Oncology Group. Proc Am Soc Clin Oncol 2008;26:707s (Abstract 19013).

Lemma GL, Loehrer PJ, Lee J, Langer C, Tester W, Johnson DH: A Phase II Study of Carboplatin plus Paclitaxel in Advanced Thymoma or Thymic Carcinoma: E1C99. (Abstract #8018, Proc Am Soc Clin Oncol, 5/2008)

Bedano PM, Perkins S, Burns M, Kessler K, Nelson R, Schneider B, Risley L, Dropcho S, Loehrer PJ: A Phase II Trial of Erlotinib plus Bevacizumab in Patients with Recurrent Thymoma or Thymic Carcinoma. (Abstract #19087, Proc Am Soc Clin Oncol, 5/2008)

Doyle D and Einhorn LH: Delayed toxicity of whole brain radiotherapy in germ cell tumor patients with CNS metastases. Proc Amer Soc Clin Oncol 25:2007 (abstract #15511)

Azar J, Schneider B, and Einhorn LH: Is the blood brain barrier relevant in metastatic germ cell cancer. Proc Amer Soc Clin Oncol 25:2007 (abstract #15618)

Ademuyiwa F, Breen T, Johnson C, White A, Yiannoutsos C, Hanna N. Multivariate analysis of prognostic variables associated with survival from a phase III study of cisplatin (P) plus etoposide (E) plus chest radiation (XRT) with or without consolidation docetaxel (D) in patients with unresectable stage III non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2007;25:426s (Abstract 7668).

Jalal S, Waterhouse D, Edelman M, Nattam S, Ansari R, Koneru K, Yu M, Shen J, Breen T, Hanna N. Pemetrexed plus cetuximab in patients (pts) with recurrent non-small cell lung cancer (NSCLC): a phase I-IIa dose-ranging study from the Hoosier Oncology Group. Proc Am Soc Clin Oncol 2007; 25:433s (Abstract 7698).

Sgroi M, Neubauer M, Ansari R, Govindan R, Bruetman D, Fisher W, Johnson C, Breen T, Yiannoutsos C, Hanna N. An analysis of elderly patients (pts) treated on a phase III trial of cisplatin (P) plus etoposide (E) with concurrent radiotherapy (CRT) followed by docetaxel (D) vs observation (O) in pts with stage III non small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2007;25:502s (Abstract 9037).

Bedano P, Edelman M, Nattam S, Waterhouse D, Shen J, Yu M, Harvey J, Vinson J, White A, Bottema B, Hanna N. A Phase I-IIa Dose Ranging Study of Pemetrexed plus Cetuximab in Patients (pts) with Recurrent Non-Small Cell Lung Cancer (NSCLC): Analysis of the Completed Phase I Portion of HOG-LUN04-79. 4th IASLC International Chicago Symposium on Malignancies of the Chest and Head and Neck 2006 (abstract 4.01.18).

Herbert S, Abonour R, and Einhorn LH: Salvage chemotherapy with high dose carboplatin and etoposide with peripheral blood stem cell transplant in patients with relapsed seminoma. Proc Amer Soc Clin Oncol 25: 248, 2007 (abstract #5054)

Bedano P, Neubauer M, Ansari R, Govindan R, Einhorn L, Bruetman D, White A, Breen T, Juliar B, Hanna N. Phase III study of cisplatin (P) plus etoposide (E) with concurrent chest radiation (XRT) followed by docetaxel (D) vs. observation in patients (pts) with stage III non-small cell lung cancer (NSCLC): an interim toxicity analysis of consolidation therapy. Proc Am Soc Clin Oncol 2006;24:374s (Abstract 7043).

Agarwala A, Einhorn L, Fisher W, Bruetman D, McClean J, Taber D, Titzer M, Juliar B, Breen T, Hanna N. Gefitinib plus celecoxib in chemotherapy-naïve patients with stage IIIB/IV non-small cell lung cancer (NSCLC): a phase II study from the Hoosier Oncology Group. Proc Am Soc Clin Oncol 2006;24:380s (Abstract 7066).

Herbert S, Einhorn LH, Brames MJ: Emetogenic potential of oral etoposide. Proc Amer Soc Clin Oncol 24:697, 2006 (abstract #18618)

Lewis DA, Brames MJ, Einhorn LH: Can patients with refractory germ cell tumors be cured after progression following high dose chemotherapy with tandem transplant? Results with paclitaxel + gemcitabine. *Proc Amer Soc Clin Oncol* 24:238, 2006 (abstract #4588)

Lewis,D, Tann M, McCool A, Kesler K, and Einhorn L: PET scan's clinical utility in detecting residual disease in postchemotherapy germ cell cancer patients. *Proc Amer Soc Clin Oncol* 23: 396, 2005 (abstract #4574)

Bedano P, Brames MJ, Einhorn LH, et al: A phase II study of cisplatin plus epirubicin in refractory germ cell tumors. *Proc Amer Soc Clin Oncol* 23:384, 2005 (abstract #4526)

Pan Chongxian, Brames MJ, Einhorn LH, et al: SELDI may facilitate the management of germ cell tumors. *Proc Amer Soc Clin Oncol* 23:397, 2005 (abstract #4580)

Kurup A, Burns M, Dropcho S, Pao W, Loehrer PJ: Phase II Study of Gefitinib Treatment in Advanced Thymic Malignancies. *Proc Am Soc Clin Oncol* 24:7068, 2005 (abstract #7068)

Moore A, Estes D, Govindan R, Vinson J, Calley C, Yu M, Einhorn L, Hanna N. A phase II trial of gefitinib in patients with chemosensitive and chemorefractory relapsed neuroendocrine cancers. A Hoosier Oncology Group Trial. *Proc Am Soc Clin Oncol* 2005;23:660s (abstract 7160).

TEXTBOOKS

Riggs H, Einhorn L, and Kesler K. Management of residual disease after therapy for mediastinal germ cell tumor and normal serum makers. In: Ferguson MK, ed. *Difficult Decisions in Thoracic Surgery: An Evidence-Based Approach*. London: Springer-Verlag; 2011

Schubert CC, Riggs H. Interdisciplinary team care of the older adult with cancer. In: Hirth V, ed. *Case-Based Geriatrics: A Global Perspective*. New York: McGraw-Hill; 2011

Bedano, PM, Schneider, BP, Miller, KD, Sledge, GW, Jr. Antiangiogenic Therapy in Breast Cancer. In: *Antiangiogenic Cancer Therapy*, Eds. DW Davis, RS Herbst, JL Abbruzzese, pp. 559-585. Boca Raton: CRC Press, 2008

Doyle D, Miller K. Development of New Targeted Therapies in Breast Cancer, In: *Advances in Breast Care Management*, WJ Gradishar, WW Wood, eds., Springer, New York, NY, 2007.

J Salter, KD Miller. Antiangiogenic Agents in Breast Cancer., In: *Breast Cancer: Translational Therapeutic Strategies*, G Lyman, H Burstein, eds., Informa Health, New York, NY, pages 269-283, 2007.

Moore AM, Sweeney CJ, Wick MR, Loehrer PJ: Thymoma and Thymic Carcinoma. In: *The Textbook of Uncommon Cancer*. Raghavan D, Brecher ML, Johnson DH, Meropol NJ, Moots PL, Rose PG, Mayer LA (Editors). John Wiley & Sons, Ltd., Chapter 20, pp 237-256, 2006

Vaena DA, Henley J, Loehrer PJ: Thymoma and Thymic Carcinoma. In: *Lung Cancer Principles and Practice (Third Edition)*. Pass HI, Carbone DP, Johnson DH, Minna JD, Turrisi AT (Editors). Lippincott, Williams & Wilkins, Philadelphia PA, Part XIII, Chapter 61, pp 867-880, 2005.

LS Budde and KD Miller. Cancer of the Breast., In: *DeVita, Hellman and Rosenberg's Cancer Principles & Practice of Oncology Review*, R Govindan, ed. Lippincott Williams & Wilkins, Philadelphia, PA, pages 261-288, 2005.

Manuscripts

Shahda S, Badve S, Burns M, Perkins S, Loehrer PJ, Sr. A Phase II Study of Erlotinib and Bevacizumab in Recurrent Thymoma and Thymic Carcinoma; *American J. Clin Oncol* (In Press)

Cardoso AA, Yanlin J, Luo M, Reed AM, Shahda S, He Y, Maitra A, Kelley MR, Fishel ML. APE1/Ref-1 Regulates STAT3 Transcriptional Activity and APE1/Ref-1–STAT3 Dual-Targeting Effectively Inhibits Pancreatic Cancer Cell Survival; *PLoS One*. 2012; 7(10): e47462.

Chiorean EG, Schneider BP, Akisik F, Perkins S, Anderson S, DeWitt J, Johnston EL, Spittler AJ, Deluca J, Johnson C, Bu G, Helft P, Howard TJ, Shahda S, Sandrasegaran K, Loehrer PJ, Cardenes H. Phase I and Pharmacodynamic Study of Sorafenib with Concurrent Radiotherapy and Gemcitabine in Locally Advanced Unresectable Pancreatic Cancer (Submitted for publication)

Safi Shahda and Muhammad Wasif Saif. Regorafenib: from bench to bedside in colorectal cancer Expert Review of Clinical Pharmacology, May 2013, Vol. 6, No. 3, Pages 243-248 (doi: 10.1586/ecp.13.11)

Shahda S, Ramanathan RK. New Targets in Advanced Colorectal Cancer: Moving Beyond EGFR and VEGF; *The International Journal of Targeted Therapy*. Published online 3/2013

Jalal S, Riggs H, Hanna N et al. Updated Survival and Outcomes for Older Adults with Inoperable Stage III Non-Small Cell Lung Cancer Treated with Cisplatin, Etoposide, and Concurrent Chest Radiation With or Without Consolidation Docetaxel: Analysis of a Phase III Trial from the Hoosier Oncology Group (HOG) and U.S. Oncology. *Annals of Oncology* (epub 2012)

Hardesty B, Ulbright TM, Touloukian C, and Einhorn LH: Case Report: Primary teratoma of the lesser sac. *Case Reports in Oncological Medicine*, 2012

Albany C, Brames MJ, Fausel C, Johnson CS and Einhorn LH: Randomized phase III double blind placebo controlled crossover study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5 day cisplatin combination chemotherapy regimens: A HOG study, JCO in press

Ramasubbaiah R, Perkins SM, Schilder J, Whalen C, Johnson CS, Callahan M, Jones T, Sutton G, Matei D.; Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group; *Gynecol Oncol*. 2011 Dec;123(3):499-504

Mulherin BP, Beck SD, Hahn NM Testicular cancer (in Essentials and Updates in Urologic Oncology, Nova Publishing Group, Editor-in-Chief Philippe E. Spiess) (accepted, in progress)

B.P. Mulherin, M.J. Brames, L.H. Einhorn. Long-term survival with paclitaxel and gemcitabine for germ cell tumors after progression following high-dose chemotherapy with tandem transplants (publication in process)

Shao M, Hollar S, Chambliss D, Schmitt J, et al. Targeting the Insulin Growth Factor and the Vascular Endothelial Growth Factor Pathways in Ovarian Cancer accepted in Molec Cancer Therapeutics pending minor revisions

Schmitt J, Matei D. Targeting angiogenesis in ovarian cancer. *Cancer Treat Rev*. 2011 Jul 14. (PMID: 21764518)

Schmitt J, Sommers S, Fisher W, Ansari R, Robin E, Koneru K, McClean J, Liu Z, Hanna N. Sunitinib plus paclitaxel in patients with advanced esophageal cancer: a phase II study from the Hoosier Oncology Group. In press, *Jrnl Thor Oncol* 2011

Lemma GL, Lee JW, Aisner SC, Langer C, Tester W, Johnson DH, Loehrer PJ. A Phase II Study of Carboplatin plus Paclitaxel in Advanced Thymoma or Thymic Carcinoma: E1C99. *Journal of Clinical Oncology* 29:2060-2065, 2011

Agarwala AK, Perkins SM, Abonour R, Brames MJ and Einhorn LH: Salvage chemotherapy with high dose carboplatin and etoposide with peripheral blood stem cell transplant in patients with relapsed seminoma. *Amer J Clin Oncol* 34:286-288, 2011.

Albany C, Jain A, Ulbright TM and Einhorn LH: Lung cancer, thyroid cancer or both: An unusual case presentation. *J Thorac Dis* 3:271-273, 2011

Schmitt J, Loehrer PJ Sr, "The Role of Chemotherapy In Advanced Thymoma." *J Thorac Oncol*. Oct 2010;5 (10Suppl 4): S 257-260. (PMID: 20859133)

Casey E, Harb W, Bradford D, Bufill J, Nattam S, Patel J, Fisher W, Latz J, Wu J, Hanna N. Randomized, double-blind, multicenter, phase II study of pemetrexed, carboplatin, bevacizumab with enzastaurin or placebo in chemo-naïve patients with stage IIIB/IV non-small cell lung cancer: Hoosier Oncology Group LUN 06-116. *J Thorac Oncol* 2010;5(11):1815-1820.

Agarwala A and Hanna N. Advanced non-small cell lung cancer: the role of maintenance therapy. *Ther Adv Med Oncol* 2010;2(1):17-23.

Tenner L and Einhorn LH: Ma-2 paraneoplastic encephalitis in the presence of bilateral testicular cancer. *JCO* 27: 57-58, 2009.

Mina L, Krop I, Zon RT, Isakoff SJ, Schneider CJ, Yu M, Johnson C, Vaughn LG, Wang Y, Hristova-Kazmierski M, Shonukan OO, Sledge GW, Miller KD. A phase II study of oral enzastaurin in patients with metastatic breast cancer previously treated with an anthracycline and a taxane containing regimen. *Invest New Drugs*. 2009 Feb 13. [Epub ahead of print]

Moore AM, Simon SR and Einhorn LH: A case of relapsed testicular cancer initially isolated to the spleen. *Amer J Clin Oncol* 32(6);639, 2009

Robert Strother and Daniela Matei: Pegylated Doxorubicin in Ovarian Cancer, *Therapeutics and Clinical Risk Management*, 2009 Jun;5(3):639-50

Doyle DM and Einhorn LH: Delayed toxicity of whole brain radiotherapy in germ cell tumor patients with central nervous system metastases. *Int J Radiation Biol and Physics* 70:1361-1364, 2008.

DM Doyle and KD Miller. Development of New Targeted Agents in Breast Cancer. *Breast Cancer* 15(1):49-56, 2008.

Pant-Purohit M, Cheng,L, and Einhorn LH: Apparent surgical cure for metastatic small cell lung cancer. *J Thorac Oncol* 3:682-683, 2008.

Agarwala A, Fisher W, Bruetman D, McClean J, Taber D, Titzer M, Juliar B, Yu M, Breen T, Einhorn L, Hanna N. Gefitinib plus celecoxib in chemotherapy-naïve patients with stage IIIB/IV non-small cell lung cancer (NSCLC): a phase II study from the Hoosier Oncology Group, *J Thorac Oncol* 2008;3:374-379.

Casey EM, Kiel PJ, Loehrer PJ: Clinical Management of Thymoma. *Hematology/Oncology Clinics of North America*, 22(3):457-573, 2008.

Ademuyiwa F and Hanna N. Cetuximab in non-small cell lung cancer. *Expert Opin Biol Ther* 2008;8(1):107-13.

Jordan Schmitt and Daniela Matei; PDGFR Inhibitors in Ovarian Cancer, *Clinical Ovarian Cancer*, 2008, (1), 120-126

Azar JM, Schneider BP and Einhorn LH: Is the blood brain barrier relevant in metastatic germ cell tumor. *Int J Rad Biol and Phy* 69:163-166, 2007.

L Mina, SE Soule, S Badve S, FL Baehner, J Baker, M Cronin, D Watson, ML Liu, GW Sledge, S Shak, and KD Miller. Predicting Response to Primary Chemotherapy: Gene Expression Profiling of Paraffin-Embedded Core Biopsy Tissue. *Breast Cancer Research and Treatment* 103(2):197-208, 2007

Ademuyiwa F, Johnson C, White A, Breen T, Harvey J, Neubauer M, Hanna N. Prognostic factors in stage III non-small cell lung cancer. *Clin Lung Ca* 2007;8:478-82.

JT Salter and KD Miller Antiangiogenic Agents in Breast Cancer.. *Cancer Investigation* 25(7):518-26, 2007

Bedano PM, Brames MJ, Williams SD, and Einhorn LH: A phase II study of cisplatin plus epirubicin salvage chemotherapy in refractory germ cell tumors. *J Clin Oncol* 24:5403-5407,2006.

Bedano P, Bonnin J, and Einhorn LH: Metachronous intracranial germinoma in a patient with a previous primary mediastinal seminoma. *J Clin Oncol* 24: 2386-2387, 2006.

Lewis D, Tann M, McCool A, Kesler K and Einhorn LH: PET scans in postchemotherapy seminoma patients with residual masses: a retrospective review from Indiana University. *J Clin Oncol* 24: Dec 1, 2006

M Pegram, D George, and KD Miller. Current Status and Future Directions of Oral Tyrosine Kinase Inhibitors in the Treatment of Cancer. *Clinical Advances in Hematology and Oncology* 4(12 Suppl 24):1-12, 2006.

Mina, L, Sledge, GW, Jr. Twenty years of systemic therapy for breast cancer. *Oncology* 20: 25-32, 2006.

Moore A, Einhorn L, Estes D, Govindan R, Axelson J, Vinson J, Breen T, Yu M, Hanna N. A phase II trial of gefitinib in patients with chemosensitive and chemorefractory relapsed neuroendocrine cancers, *Lung Cancer*, 2006;52:93-97.

Kurup A, Lin C-W, Murry D, Dobrolecki, Estes D, Yiannoustos C, Mariano L, Sidor C, Hickey R, Hanna N. Recombinant human angiostatin (rhAngiostatin) in combination with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer: a phase II study from Indiana University. *Ann Oncol* 2006;17:97-103.

Bedano P, Hanna N. Salvage therapy in patients with advanced non-small cell lung cancer, *Jrnl Thorac Oncol* 2006;1:582-587.

Bernstein E, Herbert S, Hanna N. Chemotherapy and Radiotherapy in the Treatment of Resectable Non-small Cell Lung Cancer, *Ann Surg Oncol* 2006;13 (3):291-301.

Hahn N, Hanna N. Combined Chemoradiotherapy in small cell lung cancer: *Hematol Oncol Clin N Am* 2005;19; 321-3.

Pan C-X, Loehrer P, Seitz D, Helft P, Juliar B, Ansari R, Pletcher W, Sweeney C: A Phase II Trial of Irinotecan, 5-Fluorouracil, Leucovorin Combined with Celecoxib and Glutamine as First Line Therapy for Advanced Colorectal Cancer: A Hoosier Oncology Group Study. *Oncology*, 69:63-70, 2005

Budde L, Hanna N. Antimetabolites in the management of non-small cell lung cancer. *Curr Treat Options Oncol* 2005;6(1); 83-9.

Shafqat A, Einhorn L, Hanna N, Sledge G, Hanna A, Juliar B, Monahan P, Bhatia S. Screening studies for fatigue and laboratory correlates in cancer patients undergoing treatment, *Ann of Oncol* 2005;16:1545-1550.

Agarwala A and Hanna N. Long-Term Survival in a Patient with Stage IV Non-Small Cell Lung Carcinoma Following Bone Metastectomy. *Clin Lung Ca* 2005;6:367-8.